Unicycive Therapeutics, Inc. (UNCY)
Unicycive Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Mountain View, CA, US. The stock last traded at $5.16, down 2.64% on the session, giving a market capitalisation of $137.8M. On trailing twelve-month figures it carries a trailing P/E of -3.08, a net margin of 0.0%. Its beta of 1.78 implies it has historically moved more than the broad market.
Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.
Unicycive Therapeutics, Inc. is most often compared with the following Healthcare names: